TransMedics to Report Second Quarter 2020 Financial Results on August 5, 2020

Rhea-AI Summary

TransMedics Group, Inc. (TMDX) has announced that it will release its second-quarter financial results on August 5, 2020, after market close. The management team will host a conference call at 4:30 p.m. ET to discuss the results. Investors can join the call by dialing specific numbers for domestic and international callers. TransMedics specializes in portable extracorporeal warm perfusion technology, which improves organ transplant therapy for patients with end-stage organ failure.

Positive

• TransMedics is positioned as the leader in portable warm perfusion technology for organ transplantation.
• Upcoming financial results may provide insights into growth metrics and future guidance.

Negative

• None.

ANDOVER, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter after market close on Wednesday, August 5, 2020. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

Investors interested in listening to the conference call may do so by dialing (866) 221-1172 for domestic callers or (270) 215-9603 for international callers, followed by Conference ID: 9858896. A live and archived webcast of the event will be available on the “Investors” section of the TransMedics website at https://investors.transmedics.com/. 

About TransMedics Group, Inc.

TransMedics is the world’s leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung and liver failure.

Investor Contact:
Brian Johnston
631-807-1986
Investors@transmedics.com

FAQ

When will TransMedics release its Q2 financial results?

TransMedics will release its Q2 financial results on August 5, 2020, after market close.

How can I listen to the TransMedics Q2 earnings call?

You can listen to the Q2 earnings call by dialing (866) 221-1172 for domestic callers or (270) 215-9603 for international callers.

What is TransMedics' main focus in the medical technology sector?

TransMedics focuses on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure.